Guska
PrivateLast Round
Seed
Feb 28, 2024
Total Funding Raised
$750,000
Company Overview
Guska is a biotechnology company developing oncolytic virus-based cancer therapies using AI and synthetic biology to engineer RNA viruses that selectively destroy tumor cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Guska Comparables
Compare Guska with similar companies based on industry and business-model similarity.
Guska Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Feb 28, 2024 |
Guska Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ficus Capital | Seed |
| LAB+ Company Builder | Seed |
| Institut Pasteur de Montevideo | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 1, 2026
Monthly visitors grew 73% MoM.
- Aug 22, 2025
Grew 43% QoQ from 7 to 10 employees.
Guska Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Guska's valuation, stock price, and market status.